Torrent Pharma: Q1 Net Profit after tax at Rs. 566 crores, JB Business revenues up 10%
Ahmedabad, 30th July 2026: Torrent Pharmaceuticals Limited (“Company”) today announced its financial results for the first quarter of FY27 COMPANIE’S Revenue at Rs. 4,921 crores, up by 55% YoY. Op. EBITDA* at Rs.1,664 crores, up by 61% YoY, Op. EBITDA* margin at 33.8%; Gross Margin at 76.4%. Net Profit after tax at Rs. 566 crores.
Consolidated Financial Summary:
| Results | Q1 FY27 | Q1 FY26 | YoY % | ||
| Rs cr | % | Rs cr | % | ||
| Revenues | 4,921 | 3,178 | 55% | ||
| Gross profit | 3,758 | 76.4% | 2,404 | 75.6% | 56% |
| Op. EBITDA* | 1,664 | 33.8% | 1,032 | 32.5% | 61% |
| Exceptional items | 21 | 0.4% | – | – | – |
| PAT | 566 | 11.5% | 548 | 17.2% | 3% |
| R&D spend | 172 | 4% | 157 | 5% | 10% |
Base Business
Base business revenues at Rs. 3,720 crores were up 17%, Op. EBITDA* at Rs. 1,240 crores grew by 20%, with margins of 33.3%
India:
- India revenues at Rs. 2,157 crores were up 19% vs IPM growth of 12%, as per the AIOCD PharmaTrac dataset
- Torrent is now ranked 1st in the IPM cardiac market, and continues strong outperformance in the segment
- Following a strong start, Gx Semaglutide recorded Q1 FY27 market share of 36% (oral and injectable combined), as per AIOCD PharmaTrac Data
Brazil:
- Brazil revenues at Rs. 277 crores were up 27%. Constant currency revenues at R$ 147 million were up by 3%.
- As per IQVIA, Torrent grew 21% vs market growth of 5%, aided by the performance of top brands and recent launches. Torrent has 58 products under ANVISA review
- During the quarter, the Company undertook a one-time channel inventory reduction in response to channel requests for extended credit periods amid rising interest costs. Secondary sales continue to reflect underlying demand momentum as reflected in IQVIA data.
United States:
- US revenues at Rs. 418 crores were up 36%. Constant currency revenues at US$ 44 million were up by 23%
- Performance is driven by new launches achieving targeted market share and certain one-time opportunities.
Germany:
- Germany revenues at Rs. 318 crores were up 3%. Constant currency revenues at EUR 29 million were down by 9%
- Growth continued to be impacted by supply disruption at a third-party supplier and lower tender offtake during the quarter
JB Business
| Results | Q1 FY27 | Q1 FY26 | YoY % | ||
| Rs cr | % | Rs cr | % | ||
| Revenues | 1,201 | 1,094 | 10% | ||
| Gross profit | 859 | 71.5% | 747 | 68.3% | 15% |
| Op. EBITDA* | 424 | 35.3% | 315 | 28.8% | 34% |
| Exceptional items | 19 | 1.6% | – | – | – |
* Before exceptional items and one offs
Key Performance Metrics:
- India Rx business (ex of trade generics + contrast media) at Rs. 657 cr grew by 13%
- International business (US + Emerging Markets + CDMO) revenues at Rs. 468 crores were up 12%
- CDMO business revenues at Rs. 145 crores were up 27%
Consolidated Revenue Summary
| Region | Q1 FY27 (Rs. crore) | Q1 Growth (%) | |||
| Base | JB | Total | Base | Reported | |
| Business | Business | Business | |||
| India | 2,157 | 733 | 2,890 | 19% | 60% |
| International | 1,451 | 468 | 1,919 | 19% | 57% |
| Others | 112 | – | 112 | -24% | -24% |
| Total | 3,720 | 1,201 | 4,921 | 17% | 55% |
Torrent Pharma is the flagship Company of the Torrent Group, with group revenues of approximately Rs 50,000 crores. It is ranked 5th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), Pain Management and Derma.
It is a specialty-focused company with ~75% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil and Germany. Torrent Pharma has 16 manufacturing facilities, of which 8 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing approximately 900+ scientists.
(Disclaimer: The information provided here is investment advice only. Investing in the markets is subject to risks and please consult your advisor before investing.)
(સ્પષ્ટતા: અત્રેથી આપવામાં આવતી તમામ પ્રકારની માહિતી કોઇપણ પ્રકારે રોકાણ/ ટ્રેડીંગ માટેની સલાહ નથી. બજારોમાં રોકાણ જોખમોને આધીન છે અને રોકાણ કરતા પહેલા કૃપા કરીને તમારા સલાહકારની સલાહ લો. વધુમાં અત્રે પ્રગટ થયેલા કોઇપણ સમાચાર કે વિગતો સાથે businessgujarat.in અંશતઃ કે સંપુર્સણપણે સહમત નથી.)